Veeva Systems SVP Faddis sells $205k in stock

Veeva Systems (NYSE:VEEV) SVP, General Counsel, and Secretary Jonathan Faddis sold 720 shares of Class A Common Stock on July 10, 2025, at a price of $285.62, for a total transaction value of $205,646. The sale comes as Veeva, now valued at $45 billion, trades near its 52-week high of $291.69, having delivered an impressive 31% return year-to-date. According to InvestingPro, the company maintains a GREAT financial health score, with 13 additional ProTips available in its comprehensive Research Report.

Following the transaction, Faddis directly owns 7902 shares of Veeva Systems.

The sale was executed under a Rule 10b5-1 trading plan adopted on December 19, 2024.

In other recent news, Veeva Systems has announced several key developments that are of interest to investors. The company reported strong financial performance in its first fiscal quarter, with notable contributions from its Crossix Solution, leading to increased earnings per share estimates for fiscal years 2026 and 2027 by Mizuho (NYSE:MFG) analysts. This has prompted Mizuho to raise their price target for Veeva Systems to $295, maintaining an Outperform rating. Similarly, Jefferies analysts have increased their price target to $335, citing robust margins and growth in Veeva’s commercial operations, particularly highlighting the success of Crossix and Vault CRM.

Additionally, TD Cowen adjusted its price target to $284, acknowledging the exceptional results from Veeva’s Crossix business and revising revenue and billings guidance upwards for fiscal year 2026. In strategic collaboration news, Veeva Systems has partnered with Sarah Cannon Research Institute to integrate the Veeva Clinical Platform, aiming to enhance the delivery of oncology clinical trials across its extensive network. Furthermore, Veeva announced that pharmaceutical company Astellas will implement Veeva Vault CRM as its standard for global commercial operations, including a specialized version for China. These developments reflect Veeva’s ongoing efforts to expand its influence and capabilities in the life sciences industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.